STOCKHOLM, SE / ACCESSWIRE / November 02, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company is participating at Redeye Life Science Day 2023 on November 23 at 11:30 CET, where CEO Martin Jönsson will present and answer questions about the latest developments and the company’s plans going forward.
Watch the livestream via https://www.redeye.se/events/915984/redeye-life-science-day-2023 where the presentation also will be available afterwards.
The presentation will also be available afterwards on AlzeCure’s company page at Redeye www.redeye.se/company/alzecure-pharma , and on AlzeCure’s website www.alzecurepharma.se/en/presentations-and-interviews/ .
Time: 09:00-17:00 CET, November 23, 2023
Venue: Sergelkonferensen, Mäster Samuelsgatan 42 (ground floor, Redeye building), Stockholm
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer’s disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson’s disease, as well as for depression treatment. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer’s disease and comprises two drug candidates. Painless is the company’s research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions, alternatively partnership, with other pharmaceutical companies.
FNCA Sweden AB is the company’s Certified Adviser. For more information, please visit www.alzecurepharma.se .
Image Attachments
Martin Jönsson CEO AlzeCure Pharma
Attachments
AlzeCure presents at Redeye Life Science Day on November 23
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/798793/alzecure-presents-at-redeye-life-science-day-on-november-23
TORONTO, July 28, 2025 /PRNewswire/ -- Qynapse, a technology company using AI to enhance the quantification…
MIAMI, July 28, 2025 /PRNewswire/ -- Aesthetic Partners, a leading medical aesthetics and plastic surgery…
ARLINGTON, Va., July 28, 2025 /PRNewswire/ -- IMV, part of the Science and Medicine Group…
New annual report reveals national and state-level trends across home health, hospice, and skilled nursing.…
COSTA MESA, Calif., July 28, 2025 /PRNewswire/ -- The newly founded Stuttering Treatment and Research Society…
Peer-reviewed research published in Redox Biology supports the therapeutic potential of Cannabinol (CBN) in brain…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
